Insight Molecular Diagnostics Inc. IMDX
Insight Molecular Diagnostics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 56.7% | 39.3% | 27.5% | -1.9% | 64.6% | -52.5% | — | — | — | — |
| Operating margin | -1260.8% | -3245.1% | -1672.4% | -1878.6% | -2444.3% | -2443.3% | — | — | — | — |
| Net margin | -1238.5% | -3225.0% | -1848.4% | -7609.8% | -2916.2% | -2461.5% | — | — | — | — |
| FCF margin | -625.6% | -1127.3% | -1570.6% | -5209.6% | -1737.4% | -2237.4% | — | — | — | — |
| Return on assets | -195.0% | -172.9% | -37.1% | -72.8% | -40.2% | -54.0% | -56.3% | -165.5% | -189.7% | -77.3% |
| Return on equity | 159.6% | 494.2% | -135.7% | -212.6% | -98.3% | -89.4% | -72.7% | -460.2% | -440.0% | -113.2% |
| Debt / equity | — | — | — | — | — | — | — | — | 0.42× | — |
| Current ratio | 1.27 | 1.62 | 1.49 | 2.11 | 2.77 | 1.03 | 5.17 | 1.55 | 1.91 | 2.97 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.